Product Information
14374-1-AP targets NLK in WB, IHC, ELISA applications and shows reactivity with human, mouse, rat samples.
| Tested Reactivity | human, mouse, rat |
| Cited Reactivity | human, mouse, rat |
| Host / Isotype | Rabbit / IgG |
| Class | Polyclonal |
| Type | Antibody |
| Immunogen |
CatNo: Ag5750 Product name: Recombinant human NLK protein Source: e coli.-derived, PGEX-4T Tag: GST Domain: 171-527 aa of BC064663 Sequence: NVFQNLVSCKRVFRELKMLCFFKHDNVLSALDILQPPHIDYFEEIYVVTELMQSDLHKIIVSPQPLSSDHVKVFLYQILRGLKYLHSAGILHRDIKPGNLLVNSNCVLKICDFGLARVEELDESRHMTQEVVTQYYRAPEILMGSRHYSNAIDIWSVGCIFAELLGRRILFQAQSPIQQLDLITDLLGTPSLEAMRTACEGAKAHILRGPHKQPSLPVLYTLSSQATHEAVHLLCRMLVFDPSKRISAKDALAHPYLDEGRLRYHTCMCKCCFSTSTGRVYTSDFEPVTNPKFDDTFEKNLSSVRQVKEIIHQFILEQQKGNRVPLCINPQSAAFKSFISSTVAQPSEMPPSPLVWE Predict reactive species |
| Full Name | nemo-like kinase |
| Calculated Molecular Weight | 58 kDa |
| GenBank Accession Number | BC064663 |
| Gene Symbol | NLK |
| Gene ID (NCBI) | 51701 |
| Conjugate | Unconjugated |
| Form | Liquid |
| Purification Method | Antigen affinity purification |
| UNIPROT ID | Q9UBE8 |
| Storage Buffer | PBS with 0.02% sodium azide and 50% glycerol, pH 7.3. |
| Storage Conditions | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA. |
Publications
What published studies show
The NLK Polyclonal antibody (Cat# 14374-1-AP) has 3 citations published in J Nanobiotechnology, Amino Acids, and Tumour Biology. The research fields span sepsis-induced acute lung injury and nanomedicine, diabetic nephropathy involving p38 MAPK/TGF-β/Smad signaling, and ovarian cancer drug resistance regulated by miRNA. Applications cited include WB and IHC across human, mouse, and rat species.
| Species | Application | Title |
|---|---|---|
J Nanobiotechnology Macrophage biomimetic nanoparticle-targeted functional extracellular vesicle micro-RNAs revealed via multiomics analysis alleviate sepsis-induced acute lung injury | ||
Amino Acids The renoprotective effects of taurine against diabetic nephropathy via the p38 MAPK and TGF-β/Smad2/3 signaling pathways | ||
